

Resolution

of the Federal Joint Committee (G-BA) on the Suspension of the Consultation Procedure under Section 35a paragraph 3b SGB V:

Belumosudil (chronic graft-versus-host disease);
requirement of routine practice data collection and
evaluations

of 6 November 2025

At their session on 6 November 2025, the Federal Joint Committee (G-BA) decided the following:

- I. The consultation procedure on the requirement of routine practice data collection and evaluations according to Section 35a paragraph 3b SGB V for the active ingredient belumosudil for the treatment of
"Patients from 12 years of age with chronic graft-versus-host disease (chronic GvHD) after failure of at least two previous lines of systemic therapy"
is suspended.
- II. The resolution will enter into force on the day of its publication on the website of the G-BA on 6 November 2025.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 6 November 2025

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken